SPOTLIGHT: Investors cheer Progen data


Australia's Progen Industries saw its share surge after researchers announced that its experimental liver cancer drug demonstrated statistically significant results. Patients taking PI-88 following the removal of a cancerous tumor went an average of 30 weeks before it grew back, compared to 17 weeks for patients who weren't taking the drug. Release | Report